Search | Clinical Trials Finder

Conditions: Renal Insufficiency, Chronic, Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 42
States / cities: Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more

Conditions: Hypertension
Interventions: Nebivolol, Valsartan, Nebivolol/valsartan combination; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypertension
Interventions: Carvedilol CR, Valsartan; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Stroke, Acute
Interventions: Valsartan; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertension
Interventions: valsartan+amlodipine combination, valsartan, amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Valsartan + HCTZ, Valsartan, HCTZ; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 70 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Escondido, California + 17 more

Conditions: Carotid Artery Diseases, Atherosclerosis
Interventions: Valsartan, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypertension
Interventions: Azilsartan medoxomil, Valsartan, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 86
States / cities: Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more

Conditions: Systolic Hypertension
Interventions: LCZ696, Valsartan, AHU377, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 19
States / cities: Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more

Conditions: METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION
Interventions: valsartan plus hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: valsartan and amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Hypertension
Interventions: LCZ696, Valsartan, AHU377, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 38
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more

Conditions: Hypertension, Metabolic Syndrome
Interventions: Aliskerin/Valsartan and Rampiril; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, Glomerulopathy (Obesity-associated), Glomerulonephritis, Membranous
Interventions: Aliskiren, Valsartan; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Azilsartan Medoxomil, Valsartan; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 984 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 77
States / cities: Huntsville, Alabama • Glendale, Arizona • Phoenix, Arizona + 74 more

Conditions: Hypertension
Interventions: Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ); Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypertension
Interventions: Nebivolol, Valsartan and Hydrochlorothiazide; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 135
States / cities: Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more

Conditions: Hypertension
Interventions: HCTZ + Amlodipine, Valsartan/HCTZ; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Muscle Shoals, Alabama • Westlake Village, California • Oklahoma City, Oklahoma + 2 more

Conditions: Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions: Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High; Drug
Lead sponsor: ARKAY Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Albany, New York

Conditions: Stage 1 Hypertension, Stage 2 Hypertension
Interventions: Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 4,161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 413
States / cities: Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more

Conditions: Hypertension
Interventions: Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: HYPERTENSION, HYPERCHOLESTEROLEMIA
Interventions: valsartan + simvastatin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 369 participants
Timeline: Started 2004
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Stage 2 Hypertension
Interventions: Valsartan/aliskiren, Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

24 Hour Ambulatory Cardiac Oxygen Consumption

Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

Blood Pressure Lowering in Acute Stroke Trial

Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

Effect of Valsartan on Carotid Artery Disease

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension